title: Low-dose urokinase regimen for the treatment of lower extremity arterial and graft occlusions: experience in 132 cases.
abstract: In a retrospective review, a low-dose urokinase (UK) infusion regimen (mean, 87,000 U of UK per hour and 100 U of heparin per hour) was evaluated for lower extremity arterial and graft occlusions. Results of 132 infusions in 111 patients were analyzed to determine efficacy, limb salvage, and complications. Angiographic success was achieved with 126 infusions (95%), and amelioration of presenting signs and symptoms was achieved after 116 infusions (88%). Patients who underwent additional percutaneous procedures were more likely to have a successful outcome. There was no significant difference in success rates for patients receiving low-dose heparin through the arterial sheath (n = 101) versus those receiving concomitant systemic heparinization (n = 29), (P = .08) [corrected]. Of 88 threatened extremities (with rest pain, cold, ulcers, or gangrene), nine were amputated (limb salvage = 90%), accounting for 82% (nine of 11) of amputations in the overall study. Patients with zero- or one-vessel runoff before infusion were more likely to require limb amputation compared with the group with two- or three-vessel runoff before infusion (P less than .01). Major periprocedural complications occurred in nine of 132 (7%) infusions, five of which necessitated specific surgery and/or transfusion for bleeding. Pericatheter thrombosis was not encountered in either subgroup. This standard local low-dose infusion represents a safe and effective treatment for lower extremity arterial and graft occlusions.
authors.affiliation: Miami Vascular Institute, Baptist Hospital of Miami, FL 33176.
authors.forename: S D
authors.initials: SD
authors.lastname: LeBlang
authors.forename: G J
authors.initials: GJ
authors.lastname: Becker
authors.forename: J F
authors.initials: JF
authors.lastname: Benenati
authors.forename: G
authors.initials: G
authors.lastname: Zemel
authors.forename: B T
authors.initials: BT
authors.lastname: Katzen
authors.forename: S S
authors.initials: SS
authors.lastname: Sallee
mesh_terms: D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D005431:Florida / Q000453:epidemiology; D006083:Graft Occlusion, Vascular / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007261:Infusions, Intra-Arterial; D007866:Leg / Q000098:blood supply*; D008297:Male; D012189:Retrospective Studies; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D014568:Urokinase-Type Plasminogen Activator